Institute of Pharmacy, Dept. of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
Eur J Pharm Sci. 2013 Jul 16;49(4):565-77. doi: 10.1016/j.ejps.2013.04.003. Epub 2013 Apr 12.
Standard particle size reduction techniques such as high pressure homogenization or wet bead milling are frequently used in the production of nanosuspensions. The need for micronized starting material and long process times are their evident disadvantages. Combinative particle size reduction technologies have been developed to overcome the drawbacks of the standard techniques. The H 42 combinative technology consists of a drug pre-treatment by means of spray-drying followed by standard high pressure homogenization. In the present paper, spray-drying process parameters influencing the diminution effectiveness, such as drug and surfactant concentration, were systematically analyzed. Subsequently, the untreated and pre-treated drug powders were homogenized for 20 cycles at 1500 bar. For untreated, micronized glibenclamide, the particle size analysis revealed a mean particle size of 772 nm and volume-based size distribution values of 2.686 μm (d50%) and 14.423 μm (d90%). The use of pre-treated material (10:1 glibenclamide/docusate sodium salt ratio spray-dried as ethanolic solution) resulted in a mean particle size of 236 nm and volume-based size distribution values of 0.131 μm (d50%) and 0.285 μm (d90%). These results were markedly improved compared to the standard process. The nanosuspensions were further transferred into tablet formulations. Wet granulation, freeze-drying and spray-drying were investigated as downstream methods to produce dry intermediates. Regarding the dissolution rate, the rank order of the downstream processes was as follows: Spray-drying>freeze-drying>wet granulation. The best drug release (90% within 10 min) was obtained for tablets produced with spray-dried nanosuspension containing 2% mannitol as matrix former. In comparison, the tablets processed with micronized glibenclamide showed a drug release of only 26% after 10 min. The H 42 combinative technology could be successfully applied in the production of small drug nanocrystals. A nanosuspension transfer to tablets that maintained the fast dissolution properties of the drug nanocrystals was successfully achieved.
标准的粒径减小技术,如高压匀浆或湿磨珠,经常用于纳米混悬剂的生产。需要微米化的起始材料和较长的工艺时间是它们明显的缺点。组合粒径减小技术已经被开发出来以克服标准技术的缺点。H42 组合技术由通过喷雾干燥对药物进行预处理,然后再进行标准的高压匀浆组成。在本文中,系统地分析了影响减小效果的喷雾干燥工艺参数,如药物和表面活性剂的浓度。随后,未处理和预处理的药物粉末在 1500 巴下匀浆 20 个循环。对于未处理的、微米化的格列本脲,粒度分析显示平均粒径为 772nm,体积分布值为 2.686μm(d50%)和 14.423μm(d90%)。使用预处理的材料(10:1 格列本脲/十二酸磺酸钠盐比喷雾干燥为乙醇溶液),平均粒径为 236nm,体积分布值为 0.131μm(d50%)和 0.285μm(d90%)。与标准工艺相比,这些结果有显著的改善。纳米混悬剂进一步转移到片剂制剂中。湿法制粒、冷冻干燥和喷雾干燥被研究作为生产干燥中间体的下游方法。关于溶出速率,下游工艺的顺序如下:喷雾干燥>冷冻干燥>湿法制粒。含有 2%甘露醇作为基质形成剂的喷雾干燥纳米混悬剂制成的片剂具有最佳的药物释放(10 分钟内 90%)。相比之下,用微米化的格列本脲处理的片剂在 10 分钟后仅释放了 26%的药物。H42 组合技术可成功应用于小药物纳米晶体的生产。成功地将纳米混悬剂转移到片剂中,保持了药物纳米晶体的快速溶解性能。